Enliven Therapeutics, Inc. (ELVN) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Enliven Therapeutics reported revenue of $0. Net income was -$103.7M, or -$1.83 per diluted share. Operating activities generated -$70.3M of cash, leaving -$70.5M of free cash flow. At fiscal year end, Enliven Therapeutics held $476.2M in total assets against $16.6M in total liabilities, including $98.9M of cash and equivalents.
Open the full interactive Enliven Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Enliven Therapeutics Key Stats
| Share Price | $39.49 |
|---|---|
| Market Cap | $2.61B |
| 52-Week Range | $15.14 – $61.15 |
| Shares Outstanding | 66.2 million (basic, 2026 Q2) |
Enliven Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$41.7M | -$51.4M | $730,000 | -$83.5M | -$104.6M | -$119.7M |
| Pre-Tax Income | -$41.4M | -$51.4M | $1.6M | -$71.6M | -$88.8M | -$103.7M |
| Income Tax | — | — | $88,000 | $0 | $232,000 | $0 |
| Net Income | -$41.4M | -$51.4M | $1.5M | -$71.6M | -$89.0M | -$103.7M |
| Diluted EPS | -$3.53 | -$2.37 | $0.06 | -$2.01 | -$1.89 | -$1.83 |
Enliven Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$20.1M | -$29.7M | -$23.6M | -$32.5M |
| Diluted EPS | -$0.32 | -$0.52 | -$0.38 | -$0.49 |
Enliven Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $47.7M | $48.3M | $88.2M | $100.1M | $124.1M | $98.9M |
| Current Assets | $90.4M | $92.7M | $89.6M | $266.2M | $318.1M | $474.9M |
| Total Assets | $90.8M | $93.6M | $92.0M | $271.9M | $325.8M | $476.2M |
| Current Liabilities | $6.2M | $7.2M | $1.8M | $25.9M | $15.9M | $16.6M |
| Total Liabilities | $6.4M | $7.6M | $1.8M | $26.0M | $15.9M | $16.6M |
| Shareholders' Equity | $84.4M | $86.0M | $90.1M | $245.9M | $309.8M | $459.6M |
Enliven Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$37.4M | -$46.8M | -$35.6M | -$61.3M | -$73.2M | -$70.3M |
| Cash From Investing | -$16.7M | -$1.6M | $76.5M | -$148.4M | -$36.0M | -$173.8M |
| Cash From Financing | $96.9M | $49.1M | -$1.2M | $234.3M | $133.2M | $218.9M |
| Free Cash Flow | -$37.4M | -$46.8M | -$35.9M | -$61.4M | -$73.2M | -$70.5M |
Figures from Enliven Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Enliven Therapeutics financials page for every line item.
Enliven Therapeutics Company Profile
| Ticker | ELVN |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Burlingame, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer |
| SEC CIK | 0001672619 |
Frequently Asked Questions
What was Enliven Therapeutics' revenue in fiscal 2025?
Enliven Therapeutics (ELVN) reported revenue of $0 for fiscal 2025.
What is Enliven Therapeutics' annual revenue history?
Enliven Therapeutics' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Enliven Therapeutics' net income in fiscal 2025?
Enliven Therapeutics reported net income of -$103.7M for fiscal 2025.
What was Enliven Therapeutics' earnings per share (EPS) in fiscal 2025?
Enliven Therapeutics' diluted EPS was -$1.83 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Enliven Therapeutics generate in fiscal 2025?
Enliven Therapeutics generated -$70.5M of free cash flow in fiscal 2025.
What was Enliven Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Enliven Therapeutics reported revenue of $0.
How many shares of Enliven Therapeutics are outstanding?
Enliven Therapeutics reported a weighted average of 66.2 million basic shares outstanding in 2026 Q2.
What is Enliven Therapeutics' market cap?
Based on its latest closing price, Enliven Therapeutics (ELVN) has a market capitalization of about $2.61B.
When does Enliven Therapeutics' fiscal year end?
Enliven Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Enliven Therapeutics headquartered?
Enliven Therapeutics lists its business address in Burlingame, California in its SEC filings.